Digistain: A Novel, Rapid, and Cost-effective Prognostic Marker for Guiding Adjuvant Therapy in ER+, HER2-Breast Cancer

被引：0
|
作者：
Amrania, Hemmel [1 ]
机构：
[1] Imperial Coll London, Harrow, Middx, England
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387998
引用
收藏
页码：S321 / S321
页数：1
相关论文
共 50 条
  • [41] Identification of proteomics-based biomarkers for ER+/HER2-breast cancer stratification: Implications on clinical outcome
    Wang, Guisong
    Shah, Punit
    Searfoss, Rick
    Campbell, J. Leigh Fantacone
    Hooke, Jeffrey A.
    Deyarmin, Brenda
    Zingmark, Rebecca N.
    Somiari, Stella
    Liu, Jianfang
    Kvecher, Leonid
    Sturtz, Lori A.
    Raj-Kumar, Praveen-Kumar
    Granger, Elder
    Vahdat, Linda
    Cutler, Mary L.
    Sarangarajan, Rangaprasad
    Hu, Hai
    Kiebish, Michael A.
    Kovatich, Albert J.
    Narain, Niven R.
    Shriver, Craig D.
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [42] Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective?
    Naeim, A
    Keeler, EB
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (01) : 81 - 89
  • [43] Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim, A
    Keeler, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 92S - 92S
  • [44] BREAST-CANCER - ARE IMAGING STUDIES COST-EFFECTIVE FOLLOWING BREAST-CANCER AND ADJUVANT THERAPY
    GRUNDFESTBRONIATOWSKI, S
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (04) : R13 - +
  • [45] The impact of de-escalation of adjuvant systemic therapy on the outcome of women with early ER+/HER2+breast cancer
    Horvat, V. Jeric
    Manevski, D.
    Perme, M. Pohar
    Gazic, B.
    Drev, P.
    Ribnikar, D.
    Matos, E.
    Seruga, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S423 - S423
  • [46] Genomic characterization and oncology outcomes of a locally advanced ER+/HER2-breast cancer cohort treated with neoadjuvant chemotherapy
    Abreu, Maira
    Furlan, Larissa
    Ma, Yutong
    Chen, Hanlin
    Ferreira, Carla
    Fares, Aline
    Constantino, Eduardo
    Nora, Gustavo R.
    Lucio, Gabriela
    Colombo, Tatiana
    Liu, Rui
    Wu, Xue
    Ou, Qiuxiang
    Araujo, Daniel V.
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [47] Decentral gene expression analysis for ER+/Her2-breast cancer: results of a proficiency testing program for the EndoPredict assay
    Denkert, Carsten
    Kronenwett, Ralf
    Schlake, Werner
    Bohmann, Kerstin
    Penzel, Roland
    Weber, Karsten E.
    Hoefler, Heinz
    Lehmann, Ulrich
    Schirmacher, Peter
    Specht, Katja
    Rudas, Margaretha
    Kreipe, Hans-Heinrich
    Schraml, Peter
    Schlake, Gudrun
    Bago-Horvath, Zsuzsanna
    Tiecke, Frank
    Varga, Zsuzsanna
    Moch, Holger
    Schmidt, Marcus
    Prinzler, Judith
    Kerjaschki, Dontscho
    Sinn, Bruno Valentin
    Mueller, Berit Maria
    Filipits, Martin
    Petry, Christoph
    Dietel, Manfred
    [J]. VIRCHOWS ARCHIV, 2012, 460 (03) : 251 - 259
  • [48] Replication of risk characterization in a cohort with women with advanced ER+/HER2-breast cancer using a new analytic tool
    Zhou, Xiaofeng
    de Luise, Cynthia
    Prince, Patricia
    Shen, Rongjun
    Luo, Kaiyi
    Louder, Anthony
    Gatto, Nicolle M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 66 - 67
  • [49] Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2-breast cancer
    Knudsen, Erik S.
    Witkiewicz, Agnieszka K.
    [J]. ONCOTARGET, 2016, 7 (43) : 69111 - 69123
  • [50] EVALUATION OF AROMATASE INHIBITOR UTILIZATION AND FAILURE IN POST-MENOPAUSAL WOMEN WITH ADVANCED ER+/HER2-BREAST CANCER
    Landsman-Blumberg, P.
    Namjoshi, M.
    Thomson, E.
    Johnson, W.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A229 - A230
12345